AC Immune Awarded Two Michael J. Fox Foundation Grants to Advance Small Molecule Parkinson’s Disease Programs
Funding to accelerate the development of first-in-class brain penetrant small molecules to inhibit a-syn aggregation and NLRP3 inflammasome activation in Parkinson’s disease (PD)
Programs targeting intracellular disease mechanisms complement AC Immune’s extensive PD portfolio and strengthen AC Immune’s Precision Medicine approach for PD
Additional validation of AC Immune’s Morphomer® small molecule platform
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it has been awarded two grants, a total of approximately USD 1.5 million, from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to develop first-in-class brain penetrant small molecules targeting alpha-synuclein (a-syn) and the (NOD)-like receptor protein 3 (NLRP3) inflammasome pathway in Parkinson’s disease (PD). These grants further expand AC Immune’s research efforts with MJFF following previous grants awarded since 2015 to support the development of a-syn-targeted brain imaging molecules.